Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India.
Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0287807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849468653930545152 |
|---|---|
| author | Puneet Misra Arvind Kumar Singh Baijayantimala Mishra Bijayini Behera Binod Kumar Patro Guruprasad R Medigeshi Hari Shanker Joshi Mohammad Ahmad Pradeep Kumar Chaturvedi Palanivel Chinnakali Partha Haldar Mohan Bairwa Pradeep Kharya Rahul Dhodapkar Ramashankar Rath Randeep Guleria Sanjay Kumar Rai Sitanshu Sekhar Kar Shashi Kant Sonali Sarkar Subrata Baidya Suneeta Meena Suprakash Mandal Surekha Kishore Tapan Majumder Vivek Hada |
| author_facet | Puneet Misra Arvind Kumar Singh Baijayantimala Mishra Bijayini Behera Binod Kumar Patro Guruprasad R Medigeshi Hari Shanker Joshi Mohammad Ahmad Pradeep Kumar Chaturvedi Palanivel Chinnakali Partha Haldar Mohan Bairwa Pradeep Kharya Rahul Dhodapkar Ramashankar Rath Randeep Guleria Sanjay Kumar Rai Sitanshu Sekhar Kar Shashi Kant Sonali Sarkar Subrata Baidya Suneeta Meena Suprakash Mandal Surekha Kishore Tapan Majumder Vivek Hada |
| author_sort | Puneet Misra |
| collection | DOAJ |
| description | Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months. |
| format | Article |
| id | doaj-art-1e2ca331c42d4bceae19cfc4fbf2a746 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-1e2ca331c42d4bceae19cfc4fbf2a7462025-08-20T03:25:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-011812e028780710.1371/journal.pone.0287807Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India.Puneet MisraArvind Kumar SinghBaijayantimala MishraBijayini BeheraBinod Kumar PatroGuruprasad R MedigeshiHari Shanker JoshiMohammad AhmadPradeep Kumar ChaturvediPalanivel ChinnakaliPartha HaldarMohan BairwaPradeep KharyaRahul DhodapkarRamashankar RathRandeep GuleriaSanjay Kumar RaiSitanshu Sekhar KarShashi KantSonali SarkarSubrata BaidyaSuneeta MeenaSuprakash MandalSurekha KishoreTapan MajumderVivek HadaRepeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months.https://doi.org/10.1371/journal.pone.0287807 |
| spellingShingle | Puneet Misra Arvind Kumar Singh Baijayantimala Mishra Bijayini Behera Binod Kumar Patro Guruprasad R Medigeshi Hari Shanker Joshi Mohammad Ahmad Pradeep Kumar Chaturvedi Palanivel Chinnakali Partha Haldar Mohan Bairwa Pradeep Kharya Rahul Dhodapkar Ramashankar Rath Randeep Guleria Sanjay Kumar Rai Sitanshu Sekhar Kar Shashi Kant Sonali Sarkar Subrata Baidya Suneeta Meena Suprakash Mandal Surekha Kishore Tapan Majumder Vivek Hada Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India. PLoS ONE |
| title | Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India. |
| title_full | Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India. |
| title_fullStr | Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India. |
| title_full_unstemmed | Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India. |
| title_short | Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India. |
| title_sort | anti sars cov 2 antibody kinetics up to 6 months of follow up result from a nation wide population based age stratified sero epidemiological prospective cohort study in india |
| url | https://doi.org/10.1371/journal.pone.0287807 |
| work_keys_str_mv | AT puneetmisra antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT arvindkumarsingh antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT baijayantimalamishra antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT bijayinibehera antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT binodkumarpatro antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT guruprasadrmedigeshi antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT harishankerjoshi antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT mohammadahmad antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT pradeepkumarchaturvedi antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT palanivelchinnakali antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT parthahaldar antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT mohanbairwa antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT pradeepkharya antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT rahuldhodapkar antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT ramashankarrath antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT randeepguleria antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT sanjaykumarrai antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT sitanshusekharkar antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT shashikant antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT sonalisarkar antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT subratabaidya antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT suneetameena antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT suprakashmandal antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT surekhakishore antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT tapanmajumder antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia AT vivekhada antisarscov2antibodykineticsupto6monthsoffollowupresultfromanationwidepopulationbasedagestratifiedseroepidemiologicalprospectivecohortstudyinindia |